Surrozen (SRZN) Free Cash Flow (2020 - 2026)
Surrozen (SRZN) posted quarterly Free Cash Flow of -$12.6 million for Q1 2026, down 35.61% year-over-year from -$19.6 million in Q1 2025, and down 113.79% quarter-over-quarter from -$5.9 million in Q4 2025.
Powered by 
Analysis
Surrozen (SRZN) Free Cash Flow (2020 - 2026) Analysis & Trends
Surrozen's Free Cash Flow history runs 7 years deep, the most recent figure standing at -$12.6 million for Q1 2026.
- In Q1 2026, Free Cash Flow fell 35.61% year-over-year to -$12.6 million; the TTM figure through Mar 2026 stood at -$33.7 million (down 85.48% YoY), while the FY2025 annual figure was -$30.4 million, down 72.48% from the prior year.
- Free Cash Flow for Q1 2026 stood at -$12.6 million, down from -$5.9 million in the prior quarter.
- The five-year high for Free Cash Flow was $3.5 million in Q4 2024, with the low at -$18.8 million in Q1 2022.
- The 5-year median for Free Cash Flow is -$8.8 million (2023), against an average of -$8.6 million.
- The sharpest annual moves came in 2023 and 2024: Free Cash Flow tumbled 2544.93% in 2023, then soared 147.92% in 2024.
- Surrozen's Free Cash Flow stood at -$276000.0 in 2022, then sank by 2544.93% to -$7.3 million in 2023, then soared by 147.92% to $3.5 million in 2024, then plunged by 268.75% to -$5.9 million in 2025, then slumped by 113.79% to -$12.6 million in 2026.
- Business Quant data shows SRZN's Free Cash Flow at -$12.6 million in Q1 2026, -$5.9 million in Q4 2025, and -$9.0 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -563.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -389.61 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 437.80 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 292.04 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 477.44 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Surrozen | 263.35 Mn | 263.35 Mn | - | -7.43 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -7.43 Mn |
| Mar 31, 2026 | -12.62 Mn |
| Dec 31, 2025 | -6.02 Mn |
| Sep 30, 2025 | -9.06 Mn |
| Jun 30, 2025 | -6.12 Mn |
| Mar 31, 2025 | -9.33 Mn |
| Dec 31, 2024 | 3.46 Mn |
| Sep 30, 2024 | -6.71 Mn |
| Jun 30, 2024 | -5.65 Mn |
| Mar 31, 2024 | -8.75 Mn |
| Dec 31, 2023 | -7.30 Mn |
| Sep 30, 2023 | -10.18 Mn |
| Jun 30, 2023 | -8.80 Mn |
| Mar 31, 2023 | -14.52 Mn |
| Dec 31, 2022 | -353,000.00 |
| Sep 30, 2022 | -14.29 Mn |
| Jun 30, 2022 | -11.42 Mn |
| Mar 31, 2022 | -18.81 Mn |
| Dec 31, 2021 | -11.87 Mn |
| Sep 30, 2021 | -14.60 Mn |